Thelansis

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare genetic thrombotic microangiopathy. It results from the dysregulation of the alternative complement pathway and is characterized by hemolytic anemia, thrombocytopenia, and acute renal dysfunction. Most cases involve uncontrolled complement activation, damaging endothelial cells. Pathogenic mutations occur in genes related to complement regulation, including CFH, CFI, CD46, C3, and CFB, along with rearrangements in CFH and related genes. Symptoms can manifest at any age, typically appearing suddenly with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure triggered by respiratory infections or gastroenteritis. In some cases, onset is gradual with recurrent subclinical symptoms like anemia and thrombocytopenia, along with vague symptoms like fatigue and loss of appetite. Roughly half of patients progress to end-stage kidney disease. Diagnosis relies on genetic testing, functional complement protein tests, and sc...

  Atypical hemolytic uremic syndrome (aHUS) is a sporadic disease characterized by lower levels of circulating red blood cells due to their destruction (hemolytic anemia), lower platelet count (thrombocytopenia) due to their consumption and the kidneys' inability to process waste products from the blood and pass them into the urine (acute kidney failure), a condition known as uremia. aHUS incidence in the United States is two people per million in the general population. The disorder is estimated to affect 11 per million people in Europe between the ages of 0 and 18. Thelansis’s “Atypical Hemolytic Uremic Syndrome (aHUS) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Aty...